Auricular cartilage as the seed in NanoACi

Why ear cartilage belongs in a joint

The surface of a healthy joint is covered by articular cartilage — a smooth, avascular tissue with almost no capacity to repair itself once damaged. Because it carries no blood supply, the usual mechanisms of healing cannot reach it. When that surface breaks down, a replacement source of cartilage-forming cells must come from elsewhere in the same patient.

For decades, ENT and plastic surgeons have taken cartilage from the concha — the bowl-shaped hollow at the centre of the ear — and used it to rebuild noses. Grafting ear cartilage into a different anatomical site is not experimental; it is a routine, well-documented operation with a long safety record. That surgical precedent matters: it confirms that the ear is an accessible, tolerated, and clinically validated donor site before NanoACi enters the picture at all.

The choice of the ear in NanoACi is not simply a matter of convenience, however. It is deliberate. Ear cartilage carries two compounding biological advantages that mesoderm-derived donor sites — including articular cartilage itself — cannot offer. Those advantages are explained in the sections that follow.

Within NanoACi, the mechanically prepared ear cartilage micrografts fill the 'seed' role in the Seed. Scaffold. Signal. triad. Tissue sampling, preparation, and delivery all take place at point of care in a single planned sitting, with no cell culture or enzyme digestion involved.

Neural-crest origin and positional plasticity

Every cell in the body carries developmental instructions that define where it belongs. In mesoderm-derived tissues — including articular cartilage — those instructions include HOX-gene expression: a positional postcode that fixes a cell's identity to a specific address along the body axis. Articular chondrocytes carry that postcode, and they tend to behave accordingly.

Ear cartilage develops by a different route. Like nasal cartilage, it originates from the neural crest — a migratory, multipotent embryonic population sometimes called the fourth germ layer. Neural-crest cells are HOX-gene-negative: they carry no fixed positional address. That absence, far from being a deficiency, confers something more useful in the context of joint repair — positional flexibility. When transplanted into a joint environment, these cells read local biological cues rather than defaulting to their tissue of origin, and adopt an identity appropriate to their new surroundings.

Research published by a Basel group demonstrated this directly: adult human neural-crest-derived cartilage cells were shown to repair articular defects. In comparative testing, they also outperformed articular chondrocytes across several measures — chondrogenic potential, proliferation rate, and deposition of type II collagen and proteoglycan, the matrix components that define functional hyaline cartilage. Equally relevant to practical cell-delivery strategies, neural-crest chondrocytes showed resistance to dedifferentiation: the gradual drift toward a fibroblast-like phenotype that tends to degrade articular chondrocyte lines when they are expanded in culture.

These are properties of the cell type, established at an experimental level. They form the biological rationale for choosing ear cartilage as the seed in NanoACi — distinct from outcome evidence for the combined technique, which is being gathered prospectively through NanoACi 100.

The perichondrium's progenitor layer

Wrapped around auricular cartilage is a layer of dense connective tissue called the perichondrium. Its inner surface is populated by undifferentiated chondroprogenitor cells — less committed cells capable of becoming cartilage-forming chondroblasts. When the ear concha is mechanically processed into micrografts, the perichondrium remains intimately attached, bringing this progenitor population into the preparation alongside the mature chondrocytes that the micrograft procedure releases.

This is a third biological layer, distinct from the two advantages described previously. Neural-crest origin and HOX-negative plasticity are properties shared with nasal cartilage. The perichondrial progenitor reservoir is more specific to the ear: auricular perichondrium is particularly rich in chondroprogenitor cells in a way that nasal cartilage does not replicate to the same degree, reinforcing the concha as the preferred donor site over other neural-crest sources.

The exact contribution these progenitors make to the final micrograft suspension has not yet been quantified. Their presence adds a second cellular category to the preparation, but the proportion they represent and the functional weight they carry in tissue repair remain to be characterised. The perichondrium is best understood as an additional biological consideration that comes with auricular harvest — not a separately measured clinical input.

Its importance to the cartilage it envelops is well illustrated by what its loss causes: in cauliflower ear, blunt trauma separates the perichondrium from the underlying cartilage, cuts off the nutritive supply, and leads to cartilage death. The perichondrium is the primary maintenance interface of auricular tissue — arriving with the micrograft as part of the same harvest, not as an afterthought.

From ear to injection: how Mytocel MSK is prepared

Mytocel MSK is the musculoskeletal application of Autologous Micrografting Technology (AMT), processed through the Rigenera system. Its preparation sequence is contained entirely within the single planned sitting in which delivery occurs — there is no separate laboratory phase, no waiting period, and no second appointment.

Tissue is sampled by needle from the patient's ear concha, the bowl-shaped hollow at the centre of the auricle. The concha is chosen deliberately: it yields the neural-crest chondrocytes and perichondrium-associated progenitors described in the preceding sections, from a donor site with decades of documented use in ENT and plastic surgery.

Once harvested, the tissue is processed mechanically through the Rigenera device. The disaggregation is physical, not chemical: there is no enzyme digestion, no cell culture, and no expansion outside the body. Chondrocytes and perichondrial progenitors remain within their native extracellular environment throughout. This distinguishes Mytocel MSK from culture-based methods such as ACI and MACI, where cells are extracted, expanded over several weeks, and reimplanted in a separate operative procedure.

The resulting micrograft suspension is combined at point of care with the cell-free type I collagen scaffold and autologous PRF immediately before delivery.

Needle delivery describes the access route — how the prepared material reaches the joint. The full procedure encompasses specialist imaging review, case selection, tissue sampling, preparation, component sequencing, and structured follow-up. Each of those steps is intrinsic to the technique.

Component evidence is not combined-protocol proof

Published studies of cartilage micrografting show sustained reductions in pain and improvements in function over years — this is the component evidence that supports the cellular arm of NanoACi. A second layer of evidence comes from Weninger et al. 2025, which examined a collagen scaffold combined with regenerative cells in Grade IV knee cartilage defects, providing published clinical support for the scaffold-and-cells pairing specifically. Both bodies of work inform the rationale for NanoACi's design.

Precision about which level of evidence is which matters here. Component studies and two-element pairings are not the same as data on the exact combined protocol. The specific three-part combination — ChondroFiller type I collagen scaffold, Mytocel MSK micrografts, and Arthrozheal PRF — has not been evaluated as a unit in randomised controlled trials. Component evidence is available; combined-protocol outcomes are being developed through NanoACi 100.

NanoACi 100 is a prospective 100-case series structured around pre-agreed endpoints: pain, function, and imaging measures collected at fixed intervals. Results are not reported until the dataset is complete; no success rates, recovery timelines, or outcome figures from NanoACi 100 are quoted in advance of that point.

This distinction — between what individual components show, what published pairings demonstrate, and what the combined technique will need to demonstrate prospectively — is the framework within which any new clinical technique builds its evidence base. Knowing where NanoACi sits within it is part of what specialist assessment involves.

What the cellular rationale means at consultation

The biology explains which cells NanoACi uses and why they were chosen. It does not predict, for any individual, whether the technique is appropriate.

Case selection draws on factors that sit outside embryology entirely: the degree of joint alignment, the presence or absence of mechanical instability, the extent and grade of cartilage loss, the patient's symptom profile, how imaging findings correlate with those symptoms, and what the patient is trying to achieve. Patients with significant malalignment, ligamentous instability, or mechanical pathology that a needle-delivered approach cannot address may be better served by osteotomy, ligament reconstruction, or arthroscopic surgery. ACI and MACI remain the appropriate surgical routes for many presentations. NanoACi occupies a specific lane — non-arthroscopic, one-stage, autologous — and suitability depends on whether a given clinical picture fits that lane.

The practical question to bring to a first appointment is not 'does the neural-crest science apply to me?' but 'does my imaging, my symptom pattern, and my goals match the profile where this approach is appropriate?' A specialist imaging review — frequently the starting point — is where that question gets answered with the precision that case selection requires.